nach oben

Erschienen in:

01.01.2012 | Original Article

Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells

verfasst von: Ching-Yuan Cheng, Shur-Hueih Cherng, Wen-Jun Wu, Tsung-Ying Yang, Xin-Yi Huang, Fu-Tien Liao, Ming-Fang Wu, Gwo-Tarng Sheu

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In terms of drug resistance, cancer cells usually benefit from high clusterin (CLU) expression on chemotherapy. In contrast, CLU expression has been found to be a favorable prognostic factor in lung cancer patients. The aims of this study are to determine the association between CLU expression and chemotherapeutic sensitivity and the potential role of CLU in migration in human non-small-cell lung cancer (NSCLC) cell lines.

Methods

The levels of clusterin in NSCLC cell lines were altered by short hairpin RNA interference (shRNAi) and overexpression on chemosensitivity assay. Migratory ability of these cell lines was also investigated.

Results

H1355 cells with the highest level of CLU demonstrated the lowest sensitivities to Adriamycin (ADR), docetaxel (DOC), and gemcitabine (GEM) treatment. Inhibition of CLU expression in H1355 cells resulted in higher chemosensitivities. When CLU was stably overexpressed in A549 and H1299 cells, only the chemosensitivity to ADR was reduced. The migratory ability of CLU-overexpressing cells significantly decreased. Moreover, MMP2 transcription was inhibited in CLU-overexpressing H1299 cells. These results indicated lower metastatic potential for cancer cells with high CLU level.

Conclusion

Lung cancer cells with high level of CLU have reduced chemosensitivity. High level of CLU may result in migratory inhibition and thus favorable prognosis in lung cancer.

Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JB Jr, Johnson DH, Lu B (2007) Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 16:1845–1851PubMedCrossRef

Blaschuk O, Burdzy K, Fritz IB (1983) Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. J Biol Chem 258:7714–7720PubMed

Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Corti A, Corvetta D, Sala A, Bettuzzi S (2005) Ca2 + depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 12:101–104PubMedCrossRef

Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, Sekhar KR, Gleave M, Freeman M, Lu B (2005) Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 63:1228–1236PubMedCrossRef

Chang JT, Chang GC, Ko JL, Liao HY, Liu HJ, Chen CC, Su JM, Lee H, Sheu GT (2006) Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer 118:317–325PubMedCrossRef

Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T, Tomita M (1992) Identification of the disulfide bonds in human plasma protein SP-40, 40 (apolipoprotein-J). J Biochem 112:557–561PubMed

Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY (2009) Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 21:704–711PubMedCrossRef

de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J (1990) Apolipoprotein J: structure and tissue distribution. Biochemistry 29:5380–5389PubMedCrossRef

Djeu JY, Wei S (2009) Clusterin and chemoresistance. Adv Cancer Res 105:77–92PubMedCrossRef

10.

Hazzaa SM, Elashry OM, Afifi IK (2010) Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 16:101–109PubMedCrossRef

11.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249PubMedCrossRef

12.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME (2004) Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3:223–232PubMedCrossRef

13.

Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA (2003) Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 278:11590–11600PubMedCrossRef

14.

Lourda M, Trougakos IP, Gonos ES (2007) Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 120:611–622PubMedCrossRef

15.

Miyake H, Hara I, Fujisawa M, Gleave ME (2006) The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 15:507–517PubMedCrossRef

16.

Miyake H, Hara S, Arakawa S, Kamidono S, Hara I (2002) Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J Urol 167:703–706PubMedCrossRef

17.

Panico F, Rizzi F, Fabbri LM, Bettuzzi S, Luppi F (2009) Clusterin (CLU) and lung cancer. Adv Cancer Res 105:63–76PubMedCrossRef

18.

Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, Song Y (2010) The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 28:661–669PubMedCrossRef

19.

Reddy KB, Jin G, Karode MC, Harmony JA, Howe PH (1996) Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 35:6157–6163PubMedCrossRef

20.

Sakai I, Miyake H, Takenaka A, Fujisawa M (2009) Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104:942–946PubMedCrossRef

21.

Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ (2004) Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 91:1842–1850PubMedCrossRef

22.

Watari H, Kanuma T, Ohta Y, Hassan MK, Mitamura T, Hosaka M, Minegishi T, Sakuragi N (2010) Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy. Pathol Oncol Res 16:345–352PubMedCrossRef

23.

Wong P, Taillefer D, Lakins J, Pineault J, Chader G, Tenniswood M (1994) Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur J Biochem 221:917–925PubMedCrossRef

24.

Zoubeidi A, Chi K, Gleave M (2010) Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 16:1088–1093PubMedCrossRef

Titel: Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells
verfasst von: Ching-Yuan Cheng
Shur-Hueih Cherng
Wen-Jun Wu
Tsung-Ying Yang
Xin-Yi Huang
Fu-Tien Liao
Ming-Fang Wu
Gwo-Tarng Sheu
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1682-0

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells